Johanna Strotmann1, Henrik Fox1, Thomas Bitter1, Odile Sauzet2,3, Dieter Horstkotte1, Olaf Oldenburg4. 1. Clinic for Cardiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Georgstraße 11, 32545, Bad Oeynhausen, Germany. 2. Statistik-Beratung-Centrum (StatBeCe) Zentrum für Statistik, Bielefeld University, Bielefeld, Germany. 3. Epidemiology and International Public Health, Bielefeld School of Public Health, Bielefeld University, Bielefeld, Germany. 4. Clinic for Cardiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Georgstraße 11, 32545, Bad Oeynhausen, Germany. akleemeyer@hdz-nrw.de.
Abstract
BACKGROUND: Sleep-disordered breathing (SDB) represents a common and highly relevant co-morbidity in patients with atrial fibrillation (Afib). Obstructive sleep apnea (OSA) has been identified as an independent risk factor for developing Afib and for Afib recurrence after treatment, but the role of central sleep apnea (CSA) is less clear. This study investigated characteristics of SDB in Afib patients with preserved left ventricular ejection fraction (PEF). METHODS AND RESULTS: Consecutive patients (07/2007 to 03/2016) with documented Afib at hospital admission and PEF undergoing 6-channel cardiorespiratory polygraphy (PG) screening were retrospectively analyzed. A total of 211 patients were included (146 men; age 68.7 ± 8.5 years). Only 6.6% of patients had no SDB (apnea-hypopnea index [AHI] < 5/h). When moderate-to-severe SDB (AHI ≥ 15/h) was classified based on the predominant type of apneas and hypopneas, OSA (≥ 80% obstructive events) was found in 15% of patients, CSA (≥ 80% central events) in 10%, and 36% had mixed sleep apnea. For patients with Cheyne-Stokes respiration (CSR; 34%), time spent in CSR increased significantly as total AHI increased (p < 0.001); total CSR duration was 20, 50, and 117 min, respectively, in patients with mild, moderate, and severe SDB. CONCLUSIONS: SDB was highly prevalent in this cohort of patients with Afib and PEF. The proportion of patients with moderate-to-severe OSA, for whom treatment is recommended by current guidelines, was about 15%. With 36% of patients presenting with moderate-to-severe mixed sleep apnea and almost 10% of patients having CSA, treatment guidelines for these types of SDB in the setting of Afib are needed.
BACKGROUND:Sleep-disordered breathing (SDB) represents a common and highly relevant co-morbidity in patients with atrial fibrillation (Afib). Obstructive sleep apnea (OSA) has been identified as an independent risk factor for developing Afib and for Afib recurrence after treatment, but the role of central sleep apnea (CSA) is less clear. This study investigated characteristics of SDB in Afib patients with preserved left ventricular ejection fraction (PEF). METHODS AND RESULTS: Consecutive patients (07/2007 to 03/2016) with documented Afib at hospital admission and PEF undergoing 6-channel cardiorespiratory polygraphy (PG) screening were retrospectively analyzed. A total of 211 patients were included (146 men; age 68.7 ± 8.5 years). Only 6.6% of patients had no SDB (apnea-hypopnea index [AHI] < 5/h). When moderate-to-severe SDB (AHI ≥ 15/h) was classified based on the predominant type of apneas and hypopneas, OSA (≥ 80% obstructive events) was found in 15% of patients, CSA (≥ 80% central events) in 10%, and 36% had mixed sleep apnea. For patients with Cheyne-Stokes respiration (CSR; 34%), time spent in CSR increased significantly as total AHI increased (p < 0.001); total CSR duration was 20, 50, and 117 min, respectively, in patients with mild, moderate, and severe SDB. CONCLUSIONS: SDB was highly prevalent in this cohort of patients with Afib and PEF. The proportion of patients with moderate-to-severe OSA, for whom treatment is recommended by current guidelines, was about 15%. With 36% of patients presenting with moderate-to-severe mixed sleep apnea and almost 10% of patients having CSA, treatment guidelines for these types of SDB in the setting of Afib are needed.
Authors: Apoor S Gami; Dave O Hodge; Regina M Herges; Eric J Olson; Jiri Nykodym; Tomas Kara; Virend K Somers Journal: J Am Coll Cardiol Date: 2007-01-22 Impact factor: 24.094
Authors: P A Lanfranchi; A Braghiroli; E Bosimini; G Mazzuero; R Colombo; C F Donner; P Giannuzzi Journal: Circulation Date: 1999-03-23 Impact factor: 29.690
Authors: Felipe N Albuquerque; Andrew D Calvin; Fatima H Sert Kuniyoshi; Tomas Konecny; Francisco Lopez-Jimenez; Gregg S Pressman; Thomas Kara; Paul Friedman; Naser Ammash; Virend K Somers; Sean M Caples Journal: Chest Date: 2011-09-08 Impact factor: 9.410
Authors: Richard S T Leung; Matthias A Huber; Thomas Rogge; Nimrod Maimon; Kuo-Liang Chiu; T Douglas Bradley Journal: Sleep Date: 2005-12 Impact factor: 5.849
Authors: Thomas Bitter; Christoph Langer; Jürgen Vogt; Mathias Lange; Dieter Horstkotte; Olaf Oldenburg Journal: Dtsch Arztebl Int Date: 2009-03-06 Impact factor: 5.594
Authors: R Nisha Aurora; Sabin R Bista; Kenneth R Casey; Susmita Chowdhuri; David A Kristo; Jorge M Mallea; Kannan Ramar; James A Rowley; Rochelle S Zak; Jonathan L Heald Journal: J Clin Sleep Med Date: 2016-05-15 Impact factor: 4.062
Authors: Ravi Kanagala; Narayana S Murali; Paul A Friedman; Naser M Ammash; Bernard J Gersh; Karla V Ballman; Abu S M Shamsuzzaman; Virend K Somers Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Lien Desteghe; Jeroen M L Hendriks; R Doug McEvoy; Ching Li Chai-Coetzer; Paul Dendale; Prashanthan Sanders; Hein Heidbuchel; Dominik Linz Journal: Clin Res Cardiol Date: 2018-04-12 Impact factor: 5.460
Authors: Maria Tafelmeier; Teresa Weizenegger; Sarah Ripfel; Miriam Fauser; Bernhard Floerchinger; Daniele Camboni; York Zausig; Sigrid Wittmann; Marzena A Drzymalski; Florian Zeman; Christof Schmid; Lars S Maier; Stefan Wagner; Michael Arzt Journal: Clin Res Cardiol Date: 2018-06-12 Impact factor: 5.460
Authors: Muhammed Gerçek; Olaf Oldenburg; Mustafa Gerçek; Henrik Fox; Volker Rudolph; Thomas Puehler; Hazem Omran; Lisa Katharina Wolf; Kavous Hakim-Meibodi; Andreas M Zeiher; Jan Gummert; Zisis Dimitriadis Journal: J Clin Med Date: 2021-05-10 Impact factor: 4.241